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Summary. TNFα exerts apoptosis throughout an
intracellular transduction pathway that involves the
kinase proteins TRAF-2 (integration point of apoptotic
and survival signals), ASK1 (pro-apoptotic protein),
MEK-4 (p38 activator and metastasis suppressor gene),
JNK (stress mitogen activated protein kinase) and the
transcription factor AP-1. TNFα also exerts proliferation
by p38 activation, or when TRAF-2 simultaneously
induces the transcription factor NF-κB by NIK. NIK and
p38 may also be activated by IL-1. P38 activated several
transcription factors such as Elk-1, ATF-2 and NF-κB.
NIK also may activate NF-κB.
The aim of the present article was to evaluate the
different components of this TNFα/IL-1 transduction
pathway in human prostate carcinoma (PC) in
comparison with normal human prostate. In prostate
cancer, pro-apoptotic TNFα/AP-1 pathway is probably
inactivated by different factors such as p21 (at ASK-1
level) and bcl-2 (at JNK level), or diverted towards p38
or NIK activation. IL-1α enhances proliferation through
IL-1RI that activates either NIK or p38 transduction
pathway. P38 and NIK activate different transcription
factors related with cell proliferation and survival such
as ATF-2, Elk-1 or NF-κB.
In order to search a possible target to cancer prostate
treatment we proposed that inhibition of several
proinflamatory cytokines such as IL-1 and TNFα might
be a possible target for PC treatment, because decrease
the activity of all transduction pathway members that
activate transcription factors as NF-κB, Elk-1 or ATF-2.
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Introduction
Prostate cancer is the most common cancer in men
in the Western world and the second most common
cause of male cancer death. The development and
progression of prostate cancer is controlled by complex
mechanisms that are still not completely understood.
Inflammation may be a causal factor in several human
tumors, including prostate cancer. In the inflammatory
process several factors such as cytokines appear to play
crucial roles in these processes, but its role is poorly
understood. TNFα and IL-1 are two pro-inflammatory
cytokine families with multiple biological properties and
are involved in prostate cancer development (Muenchen
et al., 2000; Ricote et al., 2004).
The TNFα superfamily includes several members
such as: TNFα, TNFß, CD40L (CD40 ligand), CD30L
(CD30 ligand), CD27L (CD27 ligand), FasL (Fas
ligand), TRAIL (TNF- related apoptosis ligand), VEGF
(vascular endothelial growth factor) and APRIL (a
proliferation-inducing ligand) among other members
(Zhang, 2004). Tumor necrosis factor-α (TNFα) has
important roles in immunity and cellular remodelling, as
well as in influencing apoptosis and cell survival
(Szlosarek and Balkwill, 2003). TNFα is produced by
numerous immune cell types but also by several non-
immune cells and many kinds of tumour cells (Bazzoni
and Beutler, 1996). At present, it is assumed that TNFα
has paradoxical roles in the evolution and treatment of
malignant diseases. 
Two different TNFα receptors, named TNFRI and
TNFRII, have been identified. The binding of TNFα to
TNFRI or TNFRII induces receptor trimerization and
recruitment of several downstream signaling proteins to
their cytoplasmic domains. TNFRI is the major mediator
of TNFα activities, including programmed cell death
(apoptosis), fibroblast proliferation and antiviral activity
(Tartaglia et al., 1993). Binding of TNFα/ TNFRI
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complex to TRADD proteins (TNF receptor associated
death domain) activates TRAF-2 (one of the six
members of the TNF receptor associated factor), which
represents an integration point of pro- and anti- apoptotic
signals (Wajant and Scheurich, 2001). TRAF-2
activation might stimulate two different pathways. One
is initiated by TRAF-2 and NIK (NF-κB-inducing
kinase) interaction that activates NF-κB (nuclear factor-
kB), which promote survival factors such as bcl-2 and
bcl-XL (Tamatani et al., 1999). The other pathway
activates the cascade ASK1 (signal regulating kinase),
MEK-4 (mitogen activated protein kinase kinase 4) and
JNK (Jun N-terminal kinase) (Ichijo et al., 1996); this
latter phosphorylates AP-1 (activator protein-1), which
stimulates apoptosis either directly or by p38 activation
(Fig. 1).
In addition to TNFα (TNFα /AP1 pathway),
Interleukin-1 (IL-1) is another physiological regulator of
p38. IL-1 activates PAK-1 through its binding to two
GTPases, called Cdc42 and Rac. These activate PAK-1,
which induces MEK-6 activation that in turn activates
p38 (Raingeaud et al., 1996) (Fig. 1).
P38 was first proposed as a mitogen activated
protein kinase involved in apoptosis, although recent
studies have suggested that p38 activation is a protective
apoptotic protein (Lüschen et al., 2004). P38 regulates
gene expression by phosphorylation of some
transcription factors, including the activating
transcription factor-2 (ATF-2), the Ets-domain protein
(Elk-1) (Rao and Reddy, 1994), the cAMP-response
element binding protein (CREB) and the nuclear factor-
κB (NF-κB). 
The Interleukin-1 (IL-1) family includes two
bioactive ligands (IL-1α and IL-1ß), two types of
transmembrane receptors (IL-1RI and IL-1RII), and a
specific receptor antagonist (IL-1Rα) (Dinarello, 1998).
The affinity of IL-1α, IL-1ß and IL-1Rα to receptors IL-
1RI and IL-1RII differs according to the ligand. IL-1α
and IL-1Rα present higher affinity to IL-1RI than IL-1ß,
while IL-1ß displays higher affinity to IL-1RII (Boraschi
et al., 1996). IL-1RI has an intracellular domain that is
responsible for the initiation of the signal transduction
mechanism leading to cell proliferation activation. IL-
1RII presents an extremely short intracellular domain
that is unable to initiate signal transduction. It has been
suggested that this receptor is a natural inhibitor of IL-1
action. IL-1Rα neutralizes IL-1 action by binding to IL-
1RI and IL-1RII (Boraschi et al., 1996). 
IL-1α and IL-1ß bound to their receptors (RI and
RII) promote the association of IL-1 receptor-associated
kinase (IRAK). In humans, four different IRAK
molecules have been described: IRAK-1, -2, -M, and -4
(Cao et al., 1996). They all comprised four domains: an
N-terminal death domain, a linker region, a centrally
located classical serine/threonine kinase domain, and a
C-terminal domain. Whereas IRAK-1 and IRAK-4 have
been identified in all tissues, IRAK-2 and IRAK-M have
a narrower cellular distribution (Rosati and Martin,
2002). Genotyping methods have shown that IRAK-1
and IRAK-4 are associated with prostate cancer risk
(Sun et al., 2006). IRAK-1, the primarily described
member of the IRAK family, is a membrane proximal
serine-threonine kinase that, when it is phosphorylated,
forms a complex with TRAF-6 (TNF receptor associated
factor-6) (Cao et al., 1996). TRAF-6 interacts with the
C-terminus of IRAK-1, which contains three TRAF-6
binding sites, leading to the activation of several
downstream signaling pathways, such as the activation
of NF-κB inducing kinase termed NIK, which is a
MAP3K-related kinase that activates the IKK complex
composed of IKK-α and IKK-ß (DiDonato et al., 1997).
NIK stimulate IKK-ß, which induces IKK-α
degradation. IKK complex phosphorylates IκB,
following its ubiquitination and rapid degradation,
causing the nuclear translocation of NF-κB (Fig. 1),
which, in turn, activates target genes involved in
carcinogenesis: tumor initiation, malignant
transformation and metastasis (Wu and Kral, 2005).
Using the prostate carcinoma cell lines LNCaP, DU45
and PC3, Gasparian et al. (2002) found that increased
IKK activation leads to the activation of NF-κB. A
potential role of NF-κB in the development of different
tumors such as breast (Sovak et al., 1997), colon
(Dejardin et al., 1999), pancreas (Wang et al., 1999) and
prostate (Ross et al., 2004; Domingo-Domenech et al.,
2005; Lessard et al., 2006) have been reported.
The aim of this review was to elucidate the possible
involvement of TNFα/IL-1 transduction pathway in
prostate cancer development and its role in the
breakdown of the apoptosis-proliferation equilibrium.
We also discuss the possible use of some members of
this pathway as a potential therapeutic factor.
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Fig. 1. TNFα/IL-1 transduction pathway.
TNFα family
Tumor necrosis factor α (TNFα) seems to exert a
key role in the promotion of many tumors such as
prostate cancer. TNFα is a 17 kDa polypeptide that was
first described as a serum-derived substance that causes
tumor cell death (Carswell et al., 1975). It can induce
tumor necrosis by affecting tumor vascularization and
initiating apoptotic cell death, but paradoxically, it also
can promote cell proliferation (Szlosarek and Balkwill,
2003). 
Wise et al. (2000) presented no significant different
in TNFα serum levels between normal patients
compared with hormone sensitive and refractory prostate
cancer. Other author described high circulating levels of
TNFα in prostate cancer patients (Perambakam et al.,
2005; Li et al., 2006) but also in other prostate diseases
as the chronic prostatitis (Razumov et al., 2003; Li et al.,
2006) or in several conditions such as after transurethral
prostatic resection (Irie et al., 1999). Increased levels of
these cytokines were not correlated with PSA levels
(Pfitzenmaier et al., 2003), the most successfully and
widely used cancer serum marker. Stamey (2001)
suggested that PSA levels have little correlation with
cancer grade or with long-term outcome. Nevertheless,
as a functional product of normal prostatic epithelial
tissue, PSA levels will reflect changes due to
inflammation, trauma or benign proliferation (Roscigno
et al., 2004). The presence of high serum TNFα levels
has been associated with extent of disease (Michalaki et
al., 2004), poor prognosis and resistance to therapy (Foa
et al., 1990). These data suggest an increase of both
proliferation and apoptosis processes, which could lead
to a deregulated control cycle which favors the
increment of mutation chances and deregulates the
control proliferation/apoptosis equilibrium. 
We have previously reported that the
immunoexpression of TNFα (Fig. 2A) and its receptors
(TNFRI and TNFRII) in the cytoplasm of epithelial cells
of normal prostate samples. Immunoexpressions of
TNFα (Fig. 2B), TNFRI (Fig. 2C), and TNFRII were
also located in the cytoplasm of epithelial cells of cancer
prostate samples but are increased in comparison with
normal prostates (de Miguel et al., 2000). The
expression and action of TNFα and its receptors have
been reported in several tumors as esophageal (Hubel et
al., 2000), follicular thyroid (Zubelewicz et al., 2002),
ovarian (Rzymski et al., 2005) and breast (Garcia-Tuñon
et al., 2006) cancers. Several studies revealed that
endogenous TNFα is involved in tumour-cell growth
and stromal interactions that facilitate tumour invasion
and metastasis (Kollias et al., 1999). TNFα can also
provide a survival signal for cancer cells and, hence, it
has been referred to as a tumour-promoting factor
(Balkwill, 2002). 
Inflammation has been suggested as a causal factor
in several human tumors, including prostate cancer. In
inflammatory process several factors such cytokines has
been described, and the role of proinflammatory
cytokines, such as TNFα, has been well established in
prostate cancer. In this way, TNFα was the first cytokine
to be used in humans for cancer therapy. However, its
role in the treatment of cancer patients is debated
(Bertazza and Mocellin, 2008). Its systemic application
in patients with advanced tumor diseases provokes
toxicities, rare tumor remissions and organ failure
(Wiedenmann et al., 1989; Pilati et al., 2008). On the
other side, TNFα clearly posses antitumor effect when
we analyzed preclinical models or clinical setting
(Mocellin and Nitti, 2008). TNFα inhibitors represent a
new class of biological agents that specifically target key
in inflammatory process (Chang and Girgis, 2007) but
also immunotherapy may provide an alternative
treatment for cancer prostate and the use of vaccination
with different antigens such as TNFα is considered
attractive (García-Hernández et al., 2007). Further
investigations of this important topic are clearly
warranted. A better understanding of the members that
participate in the different signalling pathway activated
by TNFα may improve clinical management and provide
new targets for therapy in prostate cancer patients.
TNFα/AP-1 pathway
The unbalanced between proliferation and apoptosis
in human normal prostates is broken in prostate cancer.
The proliferation and apoptosis indexes were higher in
prostate cancer than in normal prostate (De Miguel et al.,
2000). This uncontrolled proliferation is characteristic of
cancer pathology. These data suggest that several factors
which regulate proliferation/apoptosis equilibrium are
altered in pathologic conditions. In this way, cells have
different mechanisms for detecting environmental
changes and developing a response. 
In all normal human prostates, positive
immunoreactions to TRAF-2, ASK1 MEK-4 and JNK
were found, although immunoreaction to AP-1 (p-c-jun)
was negative (De Miguel et al., 2000; Ricote et al.,
2003). TRAF-2 (Fig. 2D) and ASK1 (Fig. 2E) were
located in the cytoplasm of epithelial cell in normal
prostate. ASK1 is associated with apoptosis (Ricote et
al., 2003). MEK-4 preferentially accumulates in the
nucleus (Fig. 2F) and -at low levels- in the cytoplasm
(Kim et al., 2001; Ricote et al., 2003). The mechanism
that accounts for the nuclear location of this protein is
unclear, since MEK-4 is activated by a cytoplasmic
protein and phosphorylates JNK in the cytoplasm.
However, MEK-4 function may not be restricted to the
JNK signal transduction pathway because MEK-4 also
phosphorylates and activates p38, and this latter is
prelocalized in the nucleus and is rapidly exported to the
cytoplasm upon activation (Ben-Levy et al., 1998). With
these data, Ricote et al. (2003) suggest that MEK-4 is
not involved in the JNK/AP-1 pathway, although it
might be involved in the p38 activation pathway. This
hypothesis agrees with the high p38 levels found in
normal prostate in our laboratory (Royuela et al., 2002).
Therefore, the intermediate proteins (TRAF-2, ASK1
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and MEK-4) seem to be mainly involved in other
transduction pathways such as NF-κB activation or p38
pathway (Fig. 1). 
In human prostate cancer, the TNFα cascade seems
to be over-stimulated, since TNFα receptors (TNFRI and
TNFRII) present high immunoexpression (De Miguel et
al., 2000). However, the transduction pathway from
TRAF-2 to AP-1 seems to be inactive; since
immunoreaction (in the same place described in normal
prostate) to TRAF-2 (Fig. 2G), ASK-1 (Fig. 2H) and
MEK-4 (Fig. 2J) decreased and no immunoreaction to
AP-1 (Fig. 2J) was even found (Ricote et al., 2003). In
this pathology there must be several extracellular or
intracellular factors that are blocking the activation of
this transduction pathway in different steps. ASK1 might
be a critical blockage point of this transduction pathway.
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Fig. 2. TNFα immunostaining in prostate from normal men (A) and prostatic adenocarcinoma (B). TNFRI (C) in prostate cancer. TRAF-2 (D) and ASK1
(E) were found in cytoplasm of epithelial cells of normal samples whereas MEK-4 (F) was found in the nucleus of epithelial cells. TRAF-2 (G), ASK-1
(H) and MEK-4 (I) were observed in epithelial cells of prostate cancer. Ap-1 (J) was negative in prostate cancer. Scale bars: A, B, 25 µm; C-G, J, 20
µm; H, 15 µm; I, 30 µm
P21 has been reported as an ASK1 inhibitor and has
been found significantly associated with a high Gleason
score (Aaltomaa et al., 1999; Royuela et al., 2001). Bcl-2
has been postulated as a potential modulator of JNK
activation in fibroblasts. Since an increase of bcl-2 has
been reported in prostate cancer specimens (Royuela et
al., 2000), bcl-2 might be another potential inhibitor of
JNK in prostate cancer.
IL-1 family
In normal human prostate, only IL-1ß and IL-1RI
were found but not IL-1α (Fig. 3A), IL-1RII and IL-1Rα
(Ricote et al., 2004). IL-1ß and IL-1RI have also been
reported in normal nervous tissue, where their presence
has been associated with the synthesis and secretion of
NGF (neuronal growth factor) (Juric and Carman-Krzan,
2001). Hacham et al. (2002) found differential
expression between IL-1α (in organs with abundant
lymphoid cells such as lungs, small intestine, spleen and
liver) and IL-1ß (in organs with scanty lymphoid cells
such as heart, brain, muscle or kidney). In normal human
prostate, IL-1ß is located in the nuclei of both epithelial
basal cells and stromal cells. This molecule possesses a
small seven-aminoacid sequence, which is specific for
nuclear translocation (Grenfell et al., 1991). Labriola-
Tompkins et al. (1991) described that the surface of the
IL-1ß molecule presents seven non-contiguous
aminoacids, which correspond to the IL-1RI binding
site. This interaction provokes the endocytosis of the IL-
1ß/L-1RI complex. While IL-1ß enters into the nucleus
to develop its biological action, the receptor returns to
the cell surface (Lowenthal and MacDonald, 1986). 
There have been some reports on IL-1α in prostatic
tissue. Epithelial cells in tissue cultures of human benign
prostate hyperplasia (BPH), showed an overproduction
of IL-1α, which has been related to the increase of
proliferation (Giri and Ittmann, 2000). In prostatic
cancer (PC), androgen-independent PC cell lines (PC-3
and DU-145) showed IL-1α expression (Hoosein, 1998),
which has been related to a neuroendocrine phenotype
but also to growth and differentiation (Abdul and
Hoosein, 2002). 
IL-1ß immunoreaction in prostate group (Fig. 3C)
appeared in stromal cell nuclei and in both the nucleus
and cytoplasm of all epithelial cells (basal cells and tall
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Fig. 3. IL-1 family immunostaining in human prostate. IL-1α (A) was negative in normal samples. PC samples showing intense immunoreaction to IL-1α
(B) in the epithelial cell cytoplasm. Immunoreaction to IL-1ß (C) in PC samples appears in both the nucleus and cytoplasm of epithelial cells.
Immunostaining to IL-1RI (D), IL-1RII (E) and IL-1Rα (F) in PC samples appeared in the cytoplasm of epithelial cells. Scale bars: A, C-F, 20 µm; B, 15
µm
secretory cells), but immunoexpression is lower in this
group than in normal prostate group and decreasing with
Gleason grade (not found in high Gleason). The most
cancer patients studied presented immunoreaction to IL-
1α in the epithelial cell cytoplasm (Fig. 3B); IL-1RI in
both epithelial and stromal cytoplasm cells (Fig. 3D);
IL-1RII (Fig. 3E) only in the periphery of epithelial
cells; and IL-1Rα in the cytoplasm of epithelial cells
(Fig. 3F) (Ricote et al., 2004). Interaction between IL-1α
and IL-RI would be involved with the high proliferation
degree of these tumors. Endogenous IL-1α production
was associated with resistance to exogenous anti-
proliferative stimuli and the increase in the constitutive
production of IL-6 in autocrine manner (Lázár-Molnár et
al., 2000). In previous results made in our laboratory we
report increased IL-6 expression in prostatic epithelial
cells in high Gleason grade PC (Royuela et al., 2004).
Since increased IL-6 has been associated with bad
prognosis in PC (Twillie et al., 1995; Shariat et al.,
2001), evaluation of IL-1α as IL-6 inductor might be
important to assess malignancy.
Patients with cancer prostate displaying poor
differentiation presented a complete absence of IL-1ß
expression in high Gleason cancer (Ricote et al., 2004).
This finding has also been reported in other cancers
including lung (Matanic et al., 2003) or breast (Singer et
al., 2006). Expression of IL-1RII in prostate cancer
might be related to the ability of this receptor as a
natural inhibitor of IL-1 function, and this expression
could be an effort to counteract IL-1α function.
Furthermore, a complete absence of IL-1Rα (the
antagonist receptor) expression has been described
(Ricote et al., 2004). AP-1 site appears to be the most
crucial binding site for IL-1Rα promoter activity (La et
al., 2002). A previous study in our laboratory (Ricote et
al., 2003) reported the absence of AP-1 expression in
prostate cancer samples and suggests a possible genetic
regulation mechanism of cancer progression. It has been
reported that local overproduction of IL-1α and/or
underproduction of IL-1Rα predispose to the
development of cancer, and the therapeutic
administration of IL-1Rα, in experimental models, is
effective in preventing tissue damage such as leukemia,
kidney diseases and cancer (Arend, 2002). This specific
antagonist has been studied in clinical trials tested in
several tumor cell lines (Dinarello, 1998) and animals
(corneal angiogenesis in rat) (Coxon et al., 2002), in
which administration of IL-1Rα inhibits IL-1 function
and might help to prevent the aggressiveness or even to
provoke tumor regression of prostate tumors. In this
way, Lewis et al. (2006) proposed the use of IL-1
inhibition as a novel therapeutic approach in the
treatment of solid organ malignancies. In our knowledge,
at the present there are no reports with clinical studies on
IL-1 family and cancer prostate. 
P38 transduction pathway
It has been proposed that, among other cellular
responses, TNFα induces cell death, but also cell
proliferation by activation of p38. It has also been
reported that IL-1α favors cell proliferation by p38
activation (Ricote et al., 2006). 
In normal human prostate, immunoexpression to
p38, p-Elk-1 and p-ATF-2 (the downstream executors of
the p38 pathway) were present in epithelial cells, but no
immunoreaction to PAK-1 (Fig. 4A) and MEK-6 (the
upstream executors of IL-1/p38 pathway) were found
(Ricote et al., 2006). This suggests that activation of Elk-
1 and ATF-2 is triggered by TNFα/MEK-4/p38 but not
by IL-1 (Fig. 1), since in addition to the presence of
TNFα (De Miguel et al., 2000), immunoexpressions of
p38 (Royuela et al., 2002) and MEK-4 (Ricote et al.,
2003) have been demonstrated in normal prostates.
Previous reports indicate that localization of p38 is
related to their phosphorylation: inactivated (non-
phosphorylated) is located in the cytoplasm, while
phosphorylated p38 is found in the nuclei (Zheng and
Guan, 1994; Chen et al., 1997). When MAPKs are
translocated to the nucleus and are phosphorylated, they
activate transcription factors and other target proteins
(Cano and Mahadevan, 1995).
In human prostate cancer, intense immnoreaction
was observed in the cytoplasm of epithelial cells to
PAK-1 (Fig. 4B), MEK-6 (Fig. 4C) and p38 (Fig. 4D);
p-Elk-1 (Fig. 4E) immunoreaction was nuclear in 18.5%
of patients, cytoplasmic in 51.85% of patients, and both
nuclear and cytoplasmic in 29.6% of patients; and, p-
ATF-2 (Fig. 4F) immunostaining was nuclear in 25.9%
of patients and cytoplasmic in 59.2% of patients (Ricote
et al., 2006). In several patients, p-Elk-1 and p-ATF-2
change its location from the nucleus to the cytoplasm.
This fact may be related with its biological function. In
mammalian cells, endogenous p38 is present in the
nucleus but it can be exported to the cytoplasm upon
activation (Royuela et al., 2002). In the nucleus, p38
phosphorylates Elk-1, ATF-2 and also NF-κB
(Raingeaud et al., 1996). ATF-2 (Raingeaud et al., 1996)
and Elk-1 (Xiao et al., 2002) are not only a target of p38,
but also a target for JNK. Since immunoreaction to JNK
was found in normal human prostate, but not in prostate
cancer, is reasonable to suggest that the activation of
ATF-2 and Elk-1 are the consequence of p38 pathway
activation (Ricote et al., 2006). Proapoptotic effects of
TNFα/AP-1 pathway decrease, because this pathway is
inhibited by p21 at ASK1 step (Ricote et al., 2003). Cell
proliferation stimulation triggered by TNFα via p38
occurs, since intense immunoreaction to PAK-1 and
MEK-6 was found (Ricote et al., 2006), but previous
studies have shown elevated levels of IL-1 (Ricote et al.,
2004) and p38 (Royuela et al., 2002). When LNCaP cell
cultures were treatment with the p38 inhibitor, increase
the frequency of apoptosis indicating that p38 exerts an
important role in prostatic tumour promotion by TNF-α
stimulation. Hence, down-regulation of p38 activity by
specific pharmacological inhibitors may represent a
strategy to clinical improve efficacy of TNF-α in
androgen-dependent prostatic cancer (Ricote et al.,
2006). In our knowledge, at the present there are no
reports with clinical studies on p38 and prostate cancer.
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NIK transduction pathway
Several executors of the TNFα/AP-1 transduction
pathway connect with the NIK transduction pathway
triggered by IL-1 (Raingeaud et al., 1996).
In normal prostates, the cytoplasm of epithelial cells
was immunostained to TRAF-2, IRAK (Fig. 5A),
TRAF-6 (Fig. 5B), NIK, Ikkα/ß, IkBα, p-IkB (Fig. 5C)
and NF-κB-p50 (Nuñez et al., 2008). NIK seems to be
triggered by TNF/TRAF-2 or IL-1/IRAK/TRAF-6 (Fig.
1), since the presence of TNF, TNFRI and TRAF-2 has
been described (de Miguel et al., 2000; Ricote et al.,
2003), but also the presence of IL-1 family members
(Ricote et al., 2004). Activation of NF-κB requires the
successive action of NIK, IKK complex and IkB. The
transduction pathway from NIK to NF-κB seems to be
inactive because immunoreactions to IKK, IkB and NF-
κB/p50 were scanty and no immunoreaction to NF-
κB/p65 (see Fig. 5D) was found. The scanty expression
of NF-κB/p50 was localized in the cytoplasm of
epithelial cells, because the low expression of p-IkB is
unable to activate the degradation to IkB-α required for
the translocation of NF-κB to the nucleus.
In PC, the proapoptotic effect of the TNFα/AP-1
pathway decreases, because this pathway is inhibited by
p21 (at the ASK-1 step), diverging towards the p38
pathway (Ricote et al., 2003). However, TRAF-2 might
be involved in the NIK activation pathway, although
immunoexpression to TRAF-2 was detected in a low
number of cases (decreasing with Gleason grade), at the
same time that the most of theses patients were positives
to NF-κB/p50 and NF-κB/p65 (Nuñez et al., 2008).
These data, in addition to the elevated immuno-
expressions also observed in the cytoplasm of epithelial
cells to IL-1, IRAK, TRAF-6 (Fig. 5E) and NIK (Fig.
5F), compared with normal prostate, suggest that NIK is
stimulated by IL-1.
NF-κB/p50 changes its location from the cytoplasm
to the nucleus in PC patients at the same time that NF-
κB/p65 (Fig. 5I) is also expressed in the nucleus. This is
related with the increase of IkB-α (Fig. 5G) and p-IkB
(Fig. 5H) observed in PC. Shukla et al. (2004) in human
prostate described a progressive increase in the
expression of NF-κB/p65 (but not of NF-κB/p50) in PC
compared to benign samples, and this increase is
correlated to increasing levels of IkBa and its
phosphorilation. When NF-κB is located in the nucleus
(the active form) may promote cell growth and
proliferation in prostate cancer cells by regulating the
expression of c-myc, cyclin D1 or IL-6 (Chen et al.,
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Fig. 4. α-PAK was negative in normal prostate (A) but positive in the cytoplasm of epithelial cells in PC (B) samples. Immunoreaction to MEK-6 (C),
p38 (D) and p-Elk-1 (E) appeared in the cytoplasm of epithelial cells of PC samples. p-ATF-2 immunostaining was localised in the nuclei of epithelial
cells in PC (F). Scale Bar: A, C, 20 µm; B, D, 15 µm; E, F, 25 µm
2002; Suh and Rabson, 2004); but also by the up-
regulation of the expression of several anti-apoptotic
proteins, including Bcl-xL (Chen et al., 2002), the
inhibitor of apoptosis protein (IAP) (Stehlik et al., 1998)
or TRAF- 1 and 2 (Wang et al., 1998). Nuclear location
of NF-κB/p65 has been described by several authors
(Ross et al., 2004; Domingo-Domenech et al., 2005;
Lessard et al., 2006), although their results are
discrepant. Whereas Domingo-Domenech et al.
(Domingo-Domenech et al., 2005) indicate that nuclear
localization of NF-κB is an independent prognostic
factor in PC, other authors (Ross et al., 2004; Lessard et
al., 2006) concluded that NF-κB is a new predictive
marker of prostate cancer, and several authors have
proposed the use of NF-κB inhibitors as therapeutic
agents, either alone or combined with other agents. In
human prostate cancer cell lines LNCaP and DU-145,
Chen et al. (2002) described that NF-κB favors prostate
cancer progression because it is required to activate PSA
(prostate specific antigen) transcription. This
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Fig. 5. In normal prostate samples, the cytoplasm of epithelial cells presented positive immunoreaction to IRAK (A), TRAF-6 (B), p-IkB (C) and NF-κB-
p50 (D). TRAF-6 (E), NIK (F), IkB-a (G) and p-IkB (H) immunostaining appeared in the epithelial cells of PC samples. In PC, NF-κB-p65 (I) was
localized in the nuclei but also in the cytoplasm of epithelial cells. Scale bars: A, B, H, 25 µm; C, D, F, 20 µm; E, I, 15 µm; G, 30 µm
relationship between serum PSA levels and NF-κB
expression could not be confirmed by Shukla et al.
(2004) in vivo patients. PSA level in serum is a clinical
marker for BPH and prostate cancer progression;
however, this level is poorly specific, since it can be
influenced by prostatic disease, urologic manipulations,
pharmacological treatments, ejaculation, etc (Polascik et
al., 1999). In this way, Andreakos et al., (2006)
considered NIK as a potent adjuvant strategy that offers
great potential for genetic vaccine development in
mouse myeloid cells. NF-κB is involved in cell
proliferation triggered by IL-1/NIK but also by
TNF/NIK. 
New perspectives
TNF/TRAF-2 pathway may diverge to NIK but also
towards Ap-1, and this latter pathway may also diverge
towards p38, which activates different cell proliferation
transcription factors such as NF-κB, ATF-2 and Elk-1.
P38 activation is also stimulated by IL-1. The
overexpression of both ATF-2 and Elk-1 are also related
to enhanced cell proliferation and survival (Ricote et al.,
2006). These data suggest that inhibition of IL-1α might
be a possible target to cancer treatment. Nevertheless, in
addition to components of the TNFα/IL-1 transduction
pathway (NF-κB, ATF-2 and Elk-1), several proteins
involved in the cell cycle, including IFNγ, mutated p53,
cell proliferation antigen Ki-67, ERK, p21, Rb, mcl-1 or
estrogen receptors are overexpressed in PC.
Translocation of NF-κB to the nucleus in PC might
be due the overexpression of several components of the
IL-1/NIK/NF-κB or TNF/NF-κB (NIK or p38)
pathways. Since nuclear localization of NF-κB was
observed only in PC patients, it may be considered as a
marker for predicting PC. In order to search a dominant
target for therapy, it should be taken into account that PC
is a heterogeneous disease in which multiple
transduction pathways may interact in the uncontrolled
apoptosis/cell proliferation. Since we observed that
immunoexpresion of several proinflamatory cytokines
such as IL-1α or TNFα are increased in PC (de Miguel
et al., 2000; Ricote et al., 2004), inhibition of these
cytokines might be a possible target for PC treatment,
because this inhibition would decrease all the
transduction pathway members that activate several
transcription factors such as NF-κB, Elk-1 or ATF-2.
Additional fundamental research with different TNF/IL
pathway members and their correlation with clinical
experimentation will be required in the cancer prostate
field.
Acknowledgements. This work was supported by grants from the
“Ministerio de Educación y Ciencia”, Spain (SAF2007- 61928).
References
Aaltomaa S., Lipponen P., Eskelinen M., Ala-Opas M. and Kosma V.M.
(1999). Prognostic value and expression of p21 (waf1/cip1) protein
in prostate cancer. Prostate 39, 8-15. 
Abdul M. and Hoosein N. (2002). Relationship of the interleukin-1
system sith neuroendocrine and exocrine markers in human colon
cancer cells lines. Cytokine 18, 86-91. 
Andreakos E., Williams R.O., Wales J., Foxwell B.M., Feldmann M.
(2006). Activation of NF-kappaB by the intracellular expression of
NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant.
Proc. Natl. Acad. Sci. USA 103, 14459-14464.
Arend W.P. (2002). The balance between IL-1 and IL-1Rα in disease.
Cytokine Growth Factor Rev. 13, 323-340.
Balkwill F. (2002). Tumor necrosis factor or tumor promoting factor?.
Cytokine Growth Factor Rev. 13, 135-141.
Bazzoni F. and Beutler B. (1996). The tumor necrosis factor ligand and
receptor families. N. Engl. J. Med. 385, 733-736. 
Ben-Levy R., Hooper S., Wilson R., Peterso H.F. and Marshall C.J.
(1998). Nuclear export of the stress-activated protein kinase p38
mediated by its substrate MAPKAP Kinase-2. Curr. Biol. 8, 1049-
1057. 
Bertazza L. and Mocellin S. (2008). Tumor necrosis factor (TNF) biology
and cell death. Front. Biosci. 13, 2736-2743.
Boraschi D., Bossu P., Macchia G., Ruggiero P. and Tagliabue A.
(1996). Structure-function relationship in the IL-1 family. Front.
Biosci. 1, 270-308.
Cao Z., Henzel W.J. and Gao X. (1996). IRAK: a kinase associated with
the interleukin-1 receptor. Science 271, 1128-1131.
Cano E. and Mahadevan C. (1995). Parallel signal processing among
mammalian MAP kinases. Trends Biochem. Sci. 20, 117-122.
Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N. and Williamson
B. (1975). An endotoxin-induced serum factor that causes necrosis
of tumors. Proc. Natl. Acad. Sci. USA 72, 3666-3670. 
Chang J. and Girgis L. (2007). Clinical use of anti-TNF-alpha biological
agents--a guide for GPs. Aust. Fam. Physician 36, 1035-1038.
Chen C.D. and Sawyers C.L. (2002). NF-kappa B activates prostate-
specific antigen expression and is upregulated in androgen-
independent prostate cancer. Mol. Cell. Biol. 22, 2862-2870.
Chen J., Sadowski H.B., Kohanski R.A. and Wang L.H. (1997). Stat 5 is
a physiological activator of the insulin receptor. Proc. Natl. Acad.
Sci. USA 94, 2295-2300.
Coxon A., Bolon B., Estrada J., Kaufman S., Scully S., Rattan A.,
Duryea D., Hu Y., Rex K., Pacheco E., Van G., Zack D. and Feige
U. (2002). Inhibition of interleukin-1 but not tumor necrosis factor
suppresses neovascularization in rat models of corneal
angiogenesis and adjunvant arthritis. Arthritis Rheum. 46, 2604-
2612.
Dejardin E., Deregowski V., Chapelier M., Jacobs N., Gielen J., Merville
M. and Bours V. (1999). Regulation of NF-kappaB activity by I
kappaB-related proteins in adenocarcinoma cells. Oncogene 18,
2567-2577. 
De Miguel M.P., Royuela M., Bethencourt F.R., Santamaría L., Fraile B.
and Paniagua R. (2000). Immuno-expression of tumour necrosis
factor-α and its receptors 1 and 2 correlates with
proliferation/apoptosis equilibrium in normal, hyperplasic and
carcinomatous human prostate. Cytokine 5, 535-538. 
DiDonato J.A., Hayakawa M., Rothwarf D.M., Zandi E. and Karin M.
(1997). A cytokine-responsive IkappaB kinase that activates the
transcription factor NF-kappaB. Nature 388, 548-554.
Dinarello C.A. (1998). Interleukin-1, interleukin-1 receptors and
interleukin 1 receptor antagonist. Int. Rev. Immunol. 16, 457-499.
Domingo-Domenech J., Mellado B., Ferrer B., Truan D., Codony-Servat
J., Sauleda S., Alcover J., Campo E., Gascon P., Rovira A., Ross
1287
TNFα/IL-1 in human cancer prostate
J.S., Fernandez P.L. and Albanell J. (2005). Activation of nuclear
factor-kappaB in human prostate carcinogenesis and association to
biochemical relapse. Br. J. Cancer 93, 1285-1294.
Foa R., Massaia M., Cardona S., Tos A.G., Bianchi A., Attisano C.,
Guarini A., di Celle P.F. and Fierro M.T. (1990). Production of tumor
necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a
possible regulatory role of TNF in the progression of the disease.
Blood 76, 393-400.
Garcia-Tuñon I., Ricote M., Ruiz A., Fraile B., Paniagua R. and Royuela
M. (2006). Role of tumor necrosis factor-alpha and its receptors in
human benign breast lesions and tumors (in situ and infiltrative).
Cancer Sci. 97, 1044-1049.
Gasparian A.V., Yao Y.J., Kowalczyk D., Lyakh L.A., Karseladze A.,
Slaga T.J. and Budunova I.V. (2002). The role of IKK in constitutive
activation of NF-kappaB transcription factor in prostate carcinoma
cells. J. Cell Sci. 115, 141-151.
Giri D. and Ittmann M. (2000). Interleukin-1α is a paracrine inducer of
FGF7, a key epithelial growth factor in benign prostatic hyperplasia.
Am. J. Pathol. 157, 249-255.
Grenfell S., Smithers N., Witham S., Shaw A., Graber P. and Solari R.
(1991). Analysis of mutations in the putative nuclear localization
sequence of interleukin-1 beta. Biochem. J. 280, 111-116.
Hacham M., Argov S., White R.M., Segal S. and Apte R.N. (2002).
Different patterns of interleukin-1alpha and interleukin-1beta
expression in organs of normal young and old mice. Eur. Cytokine
Netw. 13, 55-65.
Hoosein N.M. (1998). Neuroendocrine and immune mediators in
prostate cancer progression. Front Biosci. 3, D1274-1279.
Hubel K., Mansmann G., Schafer H., Oberhauser F., Diehl V. and
Engert A. (2000). Increase of anti-inflammatory cytokines in patients
with esophageal cancer after perioperative treatment with G-CSF.
Cytokine 12, 1797-1800.
Ichijo H., Nishida E., Irie K., Ten Kijke P., Saitoh M. and Moriguchi T.
(1996). Induction of apoptosis by ASK-1, a mammalian MAPKKK
that activates SAPK/JNK and p38 signaling pathways. Science 275,
90-94. 
Irie A., Lee K.E., Kadowaki K., Toda K. and Yamada Y. (1999).
Elevation of serum and urine tumor necrosis factor levels after
transurethral resection of the prostate. Nippon Hinyokika Gakkai
Zasshi. 90, 502-508. 
Juric D.M. and Carman-Krzan M. (2001). Interleukin-1ß, but not IL-1α,
mediates nerve growth factor secretion from rat astrocytes via type I
IL-1 receptor. Int. J. Dev. Neurosci. 19, 675-683.
Kim H.L., Vander D.J., Yang X., Benson D.A., Dubauskas Z. and
Yoshida B.A. (2001). Mitogen-Activated protein kinase kinase 4
metastasis suppressor gene expression is inversely related to
histological pattern in advancing human prostatic cancers. Cancer
Res. 61, 2833- 2837.
Kollias G., Douni E., Kassiotis G. and Kontoyiannis D. (1999). On the
role of tumor necrosis factor and receptors in models of multiorgan
failure, rheumatoid arthritis, multiple sclerosis and inflammatory
bowel disease. Immunol. Rev. 169, 175-194.
La E., Rundhaug J.E., Pavone A. and Fisher S.M. (2002). Regulation of
trans-cription of the intracellular interleukin-1 receptor antagonist
gene AP-1 in mouse carcinoma cells. Mol. Carcinog. 33, 237-243.
Labriola-Tompkins E., Chandran C., Kaffka K.L., Biondi D., Graves B.J.,
Hatada M., Madison V.S., Karas J., Kilian P.L. and Ju G. (1991).
Identification of the discontinuous binding site in human interleukin
1b for the type I interleukin 1 receptor. Proc. Natl. Acad. Sci. USA
88, 11182-11186.
Lázár-Molnár E., Hegyesi H., Tóth S. and Falus A. (2000). Autocrine
and paracrine regulation by cytokines and growth factors in
melanoma. Cytokine 12, 547-554.
Lessard L., Karakiewicz P.I., Bellon-Gagnon P., Alam-Fahmy M., Ismail
H.A., Mes-Masson A.M. and Saad F. (2006). Nuclear localization of
nuclear factor-kappaB p65 in primary prostate tumors is highly
predictive of pelvic lymph node metastases. Clin. Cancer Res. 12,
5741-5745.
Lewis A.M., Varghese S., Xu H. and Alexander H.R. (2006). Interleukin-
1 and cancer progression: the emerging role of interleukin-1
receptor antagonist as a novel therapeutic agent in cancer
treatment. J. Transl. Med. 4, 48. 
Li S.P., Meng S.Y. and Li R. (2006). Clinical evaluation of four cytokines
in serum and prostatic fluid in chronic abacterial prostatitis.
Zhonghua Nan Ke Xue. 12, 25-27.
Lowenthal J. and MacDonald H.R. (1986). Binding and internalisation of
interleukin 1 by T cells. J. Exp. Med. 164, 1060-1074.
Lüschen S., Scherer A., Ussat S., Ungenfroren H. and Adam-Klages S.
(2004). Inhibition of p38 mitogen-activated protein kinase reduces
TNF induced activation of NF-κB, elicits caspase activity, and
enhances cytotoxicity. Exp. Cell. Res. 293, 196-206.
Matanic D., Beg-Zec Z., Stojanovic D., Matakoric N., Flego V. and
Milevoj-Ribic F. (2003). Cytokines in patients with lung cancer.
Scand. J. Immunol. 57, 173-178.
Michalaki V., Syrigos K., Charles P. and Waxman J. (2004). Serum
levels of IL-6 and TNF-alpha correlate with clinicopathological
features and patient survival in patients with prostate cancer. Br. J.
Cancer 90, 2312-2316.
Mocellin S. and Nitti D. (2008). TNF and cancer: the two sides of the
coin. Front. Biosci. 13, 2774-2783. 
Muenchen H.J., Lin D.L., Walsh M.A., Keller E.T. and Pienta K.J.
(2000). Tumor necrosis factor-alpha-induced apoptosis in prostate
cancer cells through inhibition of nuclear factor-kappaB by an
IkappaBalpha "super-repressor". Clin. Cancer Res. 6, 1969-1977.
Nuñez C., Cansino J.R., Bethencourt F., Pérez-Utrilla M., Fraile B.,
Martínez-Onsurbe P, Paniagua R and Royuela M. (2008). TNF/IL-
1/NIK/NF-κB transduction pathway: a comparative study in normal
and pathological human prostate (benign hyperplasia and
carcinoma). Histopathology (in press).
Perambakam S.M., Srivastava R. and Peace D.J. (2005). Distinct
cytokine patterns exist in peripheral blood mononuclear cell cultures
of patients with prostate cancer. Clin. Immunol. 117, 94-99. 
Pfitzenmaier J., Vessella R., Higano C.S., Noteboom J.L., Wallace D. Jr
and Corey E. (2003). Elevation of cytokine levels in cachectic
patients with prostate carcinoma. Cancer 97, 1211-1216.
Pilati P., Rossi C.R. and Mocellin S. (2008). Strategies to enhance the
anticancer potential of TNF. Front. Biosci. 13, 3181-3193. 
Polascik T.J., Oesterling J.E. and Partin A.W. (1999). Prostate specific
antigen: a decade of discovery--what we have learned and where
we are going?. J. Urol. 162, 293-306.
Rao V.N. and Reddy E.S. (1994). Elk-1 proteins interact with MAP
kinases. Oncogene 9, 1855-1582.
Raingeaud J., Whitmarsh A.J., Barrett T., Derijard B. and Davis R.J.
(1996). MKK3- and MKK6-regulated gene expression is mediated by
the p38 mitogen-activated protein kinase signal transduction
pathway. Mol. Cell. Biol. 16, 1247-1255.
Razumov S.V., Medvedev A.A., Chirun N.V., Sivkov A.V., Oshchepkov
V.N. and Siniukhin V.N. (2003). Role of cytokines in the diagnosis of
1288
TNFα/IL-1 in human cancer prostate
chronic prostatitis. Urologia 6, 25-28. 
Ricote M., Royuela M., Garcia-Tuñon I., Bethencourt F.R., Paniagua R.
and Fraile B. (2003). Pro-apoptotic tumor necrosis factor-alpha
transduction pathway in normal prostate, benign prostatic
hyperplasia and prostatic carcinoma. J. Urol. 170, 787-790.
Ricote M., Garcia-Tuñon I., Bethencourt F.R., Fraile B., Paniagua R.
and Royuela M. (2004). Interleukin-1 (IL-1alpha and IL-1beta) and
its receptors (IL-1RI, IL-1RII, and IL-1Rα) in prostate carcinoma.
Cancer 100, 1388-1396.
Ricote M., Garcia-Tunon I., Bethencourt F., Fraile B., Onsurbe P.,
Paniagua R. and Royuela M. (2006). The p38 transduction pathway
in prostatic neoplasia. J. Pathol. 208, 401-407.
Rosati O. and Martin M.U. (2002). Identification and characterization of
murine IRAK-2. Biochem. Biophys. Res. Commun. 297, 52-58.
Roscigno M., Scattoni V., Bertini R., Pasta A., Montorsi F. and Rigatti P.
(2004). Diagnosis of prostate cancer. State of the art. Minerva Urol.
Nefrol. 56, 123-145. 
Ross J.S., Kallakury B.V., Sheehan C.E., Fisher H.A., Kaufman R.P.,
Kaur P., Gray K. and Stringer B. (2004). Expression of nuclear
factor-kappa B and I kappa B alpha proteins in prostatic
adenocarcinomas: correlation of nuclear factor-kappa B
immunoreactivity with disease recurrence. Clin. Cancer Res. 10,
2466-2472.
Royuela M., De Miguel M.P., Bethencourt F., Fraile B., Arenas M.I. and
Paniagua R. (2000). IL-2, Its receptors, and bcl-2 and bax genes in
normal, hyperplastic and carcinomatous human prostates:
immunohistochemical comparative analysis. Growth Factors 18,
135-146.
Royuela M., Arenas M.I., Bethencourt F.R., Sanchez-Chapado M.,
Fraile B. and Paniagua R. (2001). Immuno expressions of p21, Rb,
mcl-1 and bad gene products in normal, hyperplastic and
carcinomatous human prostates. Eur. Cytokine Netw. 12, 654-663. 
Royuela M., Arenas M.I., Bethencourt F.R., Sánchez-Chapado M.,
Fraile B. and Paniagua R. (2002). Regulation of proliferation/
apoptosis equilibrium by mitogen-activated protein kinases in
normal, hyperplastic and carcinomatous human prostate. Hum.
Pathol. 33, 299-306.
Royuela M., Ricote M., Parsons M.S., García-Tuñón I., Paniagua R. and
de Miguel M.P. (2004). Immunohistochemical analysis of the IL-6
family of cytokines and their receptors in benign, hyperplasic and
malignant human prostate. J. Pathol. 202, 41-49.
Rzymski P., Opala T., Wilczak M., Wozniak J. and Sajdak S. (2005).
Serum tumor necrosis factor alpha receptors p55/p75 ratio and
ovarian cancer detection. Int. J. Gynaecol. Obstet. 88, 292-298.
Shariat S.F., Andrews B., Kattan M.W., Kim J., Wheeler T.M. and
Slawin K.M. (2001). Plasma levels of interleukin-6 and its soluble
receptor are associated with prostate cancer progression and
metastasis. Urology 58, 1008-1015.
Shukla S., MacLennan G.T., Fu P., Patel J., Marengo S.R., Resnick M.I.
and Gupta S. (2004). Nuclear factor-kappaB/p65 (Rel A) is
constitutively activated in human prostate adenocarcinoma and
correlates with disease progression. Neoplasia 6, 390-400.
Singer C.F., Hudelist G., Gschwantler-Kaulich D., Fink-Retter A.,
Mueller R., Walter I., Czerwenka K. and Kubista E. (2006).
Interleukin-1alpha protein secretion in breast cancer is associated
with poor differentiation and estrogen receptor alpha negativity. Int.
J. Gynecol. Cancer 16, 556-559.
Sovak M.A., Bellas R.E., Kim D.W., Zanieski G.J., Rogers A.E., Traish
A.M. and Sonenshein G.E. (1997). Aberrant nuclear factor-
kappaB/Rel expression and the pathogenesis of breast cancer. J.
Clin. Invest. 100, 2952-2960.
Suh J. and Rabson A.B. (2004). NF-kappaB activation in human
prostate cancer: important mediator or epiphenomenon? J. Cell.
Biochem. 91, 100-117.
Sun J., Wiklund F., Hsu F.C., Balter K., Zheng S.L., Johansson J.E.,
Chang B., Liu W., Li T., Turner A.R., Li L., Li G., Adami H.O., Isaacs
W.B., Xu J. and Gronberg H. (2006). Interactions of sequence
variants in interleukin-1 receptor-associated kinase4 and the toll-like
receptor 6-1-10 gene cluster increase prostate cancer risk. Cancer
Epidemiol. Biomarkers Prev. 15, 480-485.
Stamey T.A. (2001). Preoperative serum prostate-specific antigen (PSA)
below 10 microg/l predicts neither the presence of prostate cancer
nor the rate of postoperative PSA failure. Clin. Chem. 47, 631-
634.
Stehlik C., de Martin R., Binder B.R. and Lipp J. (1998). Cytokine
induced expression of porcine inhibitor of apoptosis protein (IAP)
family member is regulated by NF-kappa B. Biochem. Biophys. Res.
Commun. 243, 827-832.
Szlosarek P.W. and Balkwill F.R. (2003). Tumour necrosis factor alpha:
a potential target for the therapy of solid tumours. Oncology 4, 565-
573.
Tamatani M., Che Y.H., Matsuzaki H., Ogawa S., Okado H. and Miyake
S. (1999). Tumor necrosis factor induces Bcl-2 and Bcl-x expression
through NFκB activation in primary hippo-campal neurons. J. Biol.
Chem. 274, 8531-8538. 
Tartaglia L.A., Ayres T.M., Wong G.H. and Goeddel D.V. (1993). A
novel domain within the 55 kDa TNF receptor signals cell death. Cell
74, 845-853. 
Twillie D.A., Eisenberger M.A., Carducci M.A., Hseih W.S., Kim W.Y.
and Simons J.W. (1995). Interleukin-6: a candidate mediator of
human prostate cancer morbidity. Urology 45, 542-549.
Wajant H. and Scheurich P. (2001). Necrosis factor receptor-associated
factor (TRAF-2) and its role in TNF signaling. Int. J. Biochem. Cell.
Biol. 33, 19-32.
Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V. and Baldwin A.S.
Jr (1998). NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2
and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science
281, 1680-1683.
Wang W., Abbruzzese J.L., Evans D.B., Larry L., Cleary K.R. and Chiao
P.J. (1999). The nuclear factor-IB transcription factor is constitutively
active in human pancreatic adenocarcinoma cells. Clin. Cancer Res.
5, 119-127.
Wiedenmann B., Reichardt P., Räth U., Theilmann L., Schüle B., Ho
A.D., Schlick E., Kempeni J., Hunstein W. and Kommerell B. (1989).
Phase-I trial of intravenous continuous infusion of tumor necrosis
factor in advanced metastatic carcinomas. J. Cancer Res. Clin.
Oncol. 115, 189-192. 
Wise G.J., Marella V.K., Talluri G. and Shirazian D. (2000). Cytokine
variations in patients with hormone treated prostate cancer. J. Urol.
164, 722-725. 
Wu J.T. and Kral J.G. (2005). The NF-kappaB/IkappaB signaling
system: a molecular target in breast cancer therapy. J. Surg. Res.
23, 158-169.
Xiao D., Qu X. and Weber H.G. (2002). GRP receptor-mediated
immediate early gene expresión and transcription factor Elk-1
activation in prostate cancer cells. Regul. Peptides 109, 141-148. 
Zhang G. (2004). Tumor necrosis factor family ligand-receptor binding.
Curr. Opin. Struct. Biol. 14, 54-60.
1289
TNFα/IL-1 in human cancer prostate
Zheng C.F. and Guan K.L. (1994). Cytoplasmic localization of the
mitogen-activated protein kinase activator MEK. J. Biol. Chem. 269,
19947-19952.
Zubelewicz B., Muc-Wierzgoƒ M., Wierzgoƒ J., Romanowski W.,
Mazurek U., Wilczok T. and Podwinska E. (2002). Genetic
disregulation of gene coding tumor necrosis factor alpha receptors
(TNF alpha Rs) in follicular thyroid cancer-preliminary report. J. Biol.
Regul. Homeost. Agents 16, 98-104.
Accepted April 14, 2008
1290
TNFα/IL-1 in human cancer prostate
